OSAKA -- Sumitomo Dainippon Pharma looks to expand the applications of its drug candidate dasotraline, which has been tested in clinical trials as an ADHD treatment but now is being studied as a treatment for an eating disorder as well.
Sumitomo Dainippon expects to file a new drug application with the U.S. Food and Drug Administration in fiscal 2017 for the ADHD indication and the following year for binge eating disorder.
